BMI and BMI Percentile Change by Previous Modulator Usage
In the adult patient group, 20 patients had never used a CFTR modulator prior to initiating triple combination therapy; out of the remaining adult patients, ten transitioned directly from ivacaftor, 23 from lumacaftor/ivacaftor, and 15 from tezacaftor/ivacaftor. The patients who were modulator naïve had an average increase in BMI of 1.97 (1.86) kg/m2. Patients transitioning from ivacaftor had a mean increase in BMI of 0.54 (1.41) kg/m2. In comparison, those transitioning from lumacaftor/ivacaftor had a mean increase in BMI of 1.12 (1.31) kg/m2, and those transitioning from tezacaftor/ivacaftor experienced an average increase in BMI of 1.99 (1.60) kg/m2.
In the pediatric group, eight patients were modulator naïve, two were previously on ivacaftor, 25 were on lumacaftor/ivacaftor, and three were on tezacaftor/ivacaftor. The modulator naive group saw an average increase of the BMI percentile of 10.13 (23.01). Patients previously on lumacaftor/ivacaftor and tezacaftor/ivacaftor experienced a mean increase in BMI percentile of 9.32( 4.95) and 4 (16.7) percentile, respectively. The group with two pediatric patients who were previously on ivacaftor alone saw an average decrease in the BMI percentile of 4.5 (4.95).